期刊文献+

“重磅炸弹”药物对全球药物研发趋势的影响 被引量:2

Effects on trends of global pharmaceutical R&D by “blockbuster drugs”
原文传递
导出
摘要 本文对目前全球医药市场格局和发展情况进行了回顾和现状分析。通过归纳总结发现,畅销药的销售额占据制药企业的销售额的绝大部分。近年来,销售额超过10亿美元的"重磅炸弹"药物异军突起,成为制药企业的主要收入来源。企业不断增加投入,以期成功研发新的"重磅炸弹"药物。进一步研究得出结论,"重磅炸弹"在药品优效、科技创新、后续研究、市场培育、专利保护这5个方面具有共同的领先之处。 In this paper, current pattern of global pharmaceutical market and developments was reviewed and analyzed. By summarizing found, global pharmaceutical market structure will face great change as the result of the increasing pharmaceutical sales. Selling drugs sales accounted for the majority. "Blockbuster" drugs which mean the sales amounts achieved 1 billion became the main source of pharmaceutical companies' income. Pharma- ceutical companies expect to develop new "blockbuster" drugs successfully by investment continuous. Further study concluded there are five common features on "blockbuster" drugs: excellent efficacy, technological innovation, post-release research, market development, and patent protection.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第12期1354-1358,1397,共6页 Chinese Journal of New Drugs
关键词 “重磅炸弹”药物 新药研发 畅销药 销售额 blockbuster drugs new drug R&D selling drugs sales amount
  • 相关文献

参考文献8

二级参考文献26

  • 1赵伟晶.跨国公司在华专利战略及中国企业的对策[J].经济与管理,2006,20(2):18-21. 被引量:5
  • 2胡廷熹.2000-2005年美国市场最热销的药物[J].药学进展,2006,30(10):473-477. 被引量:5
  • 3李重锡.各国政府对干细胞研究的支持力度及其相关论文发表和专利申请[J].中国组织工程研究与临床康复,2007,11(15):2913-2918. 被引量:6
  • 4国家食品药品监督局南方医药经济研究所.2010年财富全球500强中制药企业排名[EB/OL].http://www.meinet.com.cn:8080/GlobalMedicineMarket/globalMedicineMarket/d5afe8ea618d41efb41f90088e35e12d.html,2010-7-9.
  • 5文建平.明天,谁来为医药研发埋单[N].医药经济报,2004-10-11.
  • 6唐宝莲 黄至臻.发明专利产业化的思考与对策.科技进步与对策,2003,8(6):105-107.
  • 7中国医药经济信息网.辉瑞一跨国公司业绩[EB/OL].http://ww、nmeinet.com.cn:8080/OverseasCompanvrAchievements/overseasCompanyAchievementAction.action?ocaId=4074belbcd9a49bOblc5dc56881c9fd7,2011-2-23.
  • 8SooPat.SooPat新世界专利搜索(EB/OL).http://www.soopat.corn/Patent/Result.2010-2-23.
  • 9United States Patent and Trademark Office Patent Terms Extend- ed Under 35 USC § 156 [EB/OL]. http: //vcww. usptc, gov/ patents/resources/terms/156, jsp, 2010-4-3.
  • 10Ryuhei W, Banri L. The effects of stronger intellectual proper- ty rights on technology transfer~ evidence from Japanese firm- level data[J]. Technology Transfer, 2009, 34 (2): 145-158.

共引文献36

同被引文献24

  • 1杨莉,李野.美国的药品专利连接制度研究[J].中国药房,2007,18(4):251-253. 被引量:27
  • 2MatthewHerper.全球制药公司研发绩效TOP22[EB/OL].[2014-06-16].http://www.xinyaohui.com/news/201406/16/2758.html.
  • 3U. S. Food and Drug Administration. Novel New Drugs 2014 Summary [EB/OL1. [20154)1-14]. http://www, fda. gov/downloads/drugs/devel- opmentapprovalprocess/druginnovation/ucm430299, pdf.
  • 4John Jenkins. CDER Approved Many Innovative Drugs in 2014 [EB/OL]. [2015-01-14]. http://blogs, fda. gov/fdavoiee/index, php/2015/01/cder- approved-many-innovative-drugs-in-2014.
  • 5Forbes. 2014 New Drug Approvals Hit 18-Year? High [ EB/OL]. [2015- 01-02]. http://www, forbes, eom/sites/bemardmunos/2015/01/02/the- fda-approvals-of-2014.
  • 6刘昌孝.2014欧美新药研发大丰收[N].中国科学报,20154-02-10(7).
  • 7Asher Mullard. 2014 FDA drug approvals [ J ]. Nature Rev Drug Discov, 2014 ( 13 ) : 873-875.
  • 8朱茜.全球制药企业50强揭晓诺华取代辉瑞居榜首[EB/OL][2014-06-19].http://www.qianzhan.com/analyst/detail/220/140619-03dc0772.html.
  • 9Sugar.并购,全球百强药企的“华山路”[J].健康管理,2012(3):48-52. 被引量:1
  • 10张华吉.2012年FDA批准新药简析[J].中国药物评价,2013,30(1):58-60. 被引量:3

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部